Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Intangibles (2018 - 2026)

Cytosorbents filings provide 8 years of Intangibles readings, the most recent being $3.2 million for Q4 2025.

  • On a quarterly basis, Intangibles fell 13.3% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 13.3% decrease, with the full-year FY2025 number at $3.2 million, down 13.3% from a year prior.
  • Intangibles hit $3.2 million in Q4 2025 for Cytosorbents, down from $3.6 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $4.7 million in Q4 2021 to a low of $3.2 million in Q4 2025.
  • Median Intangibles over the past 5 years was $3.7 million (2024), compared with a mean of $3.9 million.
  • Biggest five-year swings in Intangibles: rose 11.36% in 2021 and later fell 13.3% in 2025.
  • Cytosorbents' Intangibles stood at $4.7 million in 2021, then dropped by 6.62% to $4.4 million in 2022, then decreased by 11.02% to $3.9 million in 2023, then decreased by 4.75% to $3.7 million in 2024, then dropped by 13.3% to $3.2 million in 2025.
  • The last three reported values for Intangibles were $3.2 million (Q4 2025), $3.6 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.